Search Results
Your search for ,twO matches 12066 pages
Showing 3751 - 3800Risk Categories for Pediatric Patients With Medulloblastoma
In an analysis from the international phase III SJMB03 trial reported in the Journal of Clinical Oncology, Gajjar et al identified lower- and higher-risk groups of pediatric patients with medulloblastoma based on molecular and clinical risk factors. Study Details SJMB03 is a phase III trial of...
Lenalidomide Plus Epoetin Alfa vs Lenalidomide Alone in Refractory Non-del(5q) MDS
In a phase III U.S. Intergroup trial reported in the Journal of Clinical Oncology, Alan F. List, MD, and colleagues found that treatment with lenalidomide plus epoetin alfa increased the rate of major erythroid response vs lenalidomide alone in patients with lower-risk, non-del(5q) myelodysplastic...
Empowering the FDA to Require Dose Optimization of All New Oncology Drugs
The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose...
Belantamab Mafodotin-blmf in Multiple Myeloma: Number of Prior Treatments No Hindrance to Efficacy
A post hoc analysis of the phase II DREAMM-2 trial showed single-agent belantamab mafodotin-blmf to be efficacious and tolerable in patients with relapsed or refractory multiple myeloma treated with at least three prior therapies, investigators reported at the 2020 American Society of Hematology...
Anti–PD-1 Therapy Dostarlimab for dMMR Gastrointestinal Cancers: Safety and Efficacy Examined
Dostarlimab, a monoclonal antibody targeting PD-1, showed strong and durable antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues...
Does Cabozantinib Reduce Tumor Volume and Pain in Patients With NF1?
Results of a phase II trial showed that cabozantinib, a multiple tyrosine kinase receptor inhibitor, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1). These findings were published by Fisher et al in Nature Medicine. “This is the second class of...
Addition of Sitagliptin to Tacrolimus/Sirolimus Prophylaxis for Acute Graft-vs-Host Disease
In a phase II trial reported in The New England Journal of Medicine, Farag et al found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a low rate of acute graft-vs-host disease among patients with hematologic...
Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA
Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA was more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
IDH Inhibitor Ivosidenib Improves Overall Survival in Previously Treated Patients With Cholangiocarcinoma: ClarIDHy Trial
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months compared with placebo in previously treated patients with advanced IDH1-mutated cholangiocarcinoma. Researchers presented results from the global phase III ClarIDHy trial at the 2021...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
On January 15, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen....
FDA Pipeline: Two Fast Track Designations for Cavrotolimod in Nonmelanoma Skin Cancers
The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). The designations include cavrotolimod in combination with anti–PD-1 therapy for the treatment of patients with locally advanced or metastatic Merkel cell carcinoma refractory to prior...
Italian Study of Electronic Medical Record–Assisted Telephone Follow-up of Breast Cancer Survivors During the COVID-19 Pandemic
In an Italian single-institution study reported in JCO Oncology Practice, Merz et al evaluated the use of electronic medical record–assisted telephone follow-up (E-TFU) of breast cancer survivors to minimize hospital exposure over a 3-month period during the COVID-19 pandemic. The strategy was...
Expert Point of View: Ajay K. Nooka, MD, MPH
Ajay K. Nooka, MD, MPH, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be among...
New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma
B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging (BiTE) antibodies with novel targets are also achieving promising results. Studies presented at the 2020 American Society of Hematology (ASH)...
COA Submits Letter to Governors, Public Health Officials to Request Independent Oncology Practices Be Given Priority Approval to Administer COVID-19 Vaccines
Today, leadership from the Community Oncology Alliance (COA) sent a letter urging the nation's governors and public health officials to prioritize supplying cancer treatment practices with COVID-19 vaccines and allowing the practices to administer the vaccines. The letter, signed by Kashyap Patel,...
Palbociclib Plus Endocrine Therapy vs Capecitabine for Patients With HR-Positive, HER2-Negative Breast Cancer: The PEARL Trial
Although patients with hormone receptor (HR)-positive, HER2-negative, aromatase inhibitor–resistant metastatic breast cancer maintained quality of life for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy...
Adding Oxaliplatin to Fluoropyrimidine for Patients With Stage III Colon Cancer and Microsatellite Instability
In a pooled analysis reported in the Journal of Clinical Oncology, Cohen et al found that the addition of oxaliplatin to fluoropyrimidine was associated with improved overall and disease-free survival in patients with stage III colon cancer with microsatellite instability (MSI). They also found the ...
Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’
Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...
Stereotactic Ablative Body Radiotherapy in Extracranial Oligometastatic Cancers
In a registry-based observational study reported in The Lancet Oncology, Chalkidou et al found that stereotactic ablative body radiotherapy (SABR) was associated with high overall survival and low rates of toxicity in patients with extracranial oligometastatic cancers. Study Details The prospective ...
Sean Khozin, MD, MPH, Named New Chief Executive Officer of ASCO’s CancerLinQ
Sean Khozin, MD, MPH, has been named Chief Executive Officer of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. A board-certified oncologist, physician-scientist, and data science expert, Dr. Khozin is a proven leader and visionary in deploying cutting-edge data science and technology...
Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma
The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 The triplet of daratumumab, pomalidomide, and low-dose dexamethasone ...
New Study Investigates Role of Ultraviolet Radiation in Conjunctival Melanoma
Ultraviolet (UV) radiation may contribute to the development of a rare type of eye cancer, conjunctival melanoma, according to research published by Mundra et al in Nature Communications. The new study has revealed similar genetic changes in patients with conjunctival melanoma to those with...
Association Between Toxoplasma gondii Infection and Risk of Glioma
A new study published by Hodge et al in the International Journal of Cancer suggests a link between Toxoplasma gondii infection and the risk of glioma in adults. The report found that people who have glioma are more likely to have antibodies to T gondii than a similar group that was cancer-free....
Maintenance Oral Azacitidine for Patients With AML in First Remission: QUAZAR AML-001 Trial
As reported in The New England Journal of Medicine by Andrew H. Wei, MBBS, PhD, and colleagues, the phase III QUAZAR AML-001 trial has shown prolonged overall survival with oral azacitidine maintenance therapy vs placebo in patients with acute myeloid leukemia (AML) in first remission. The oral...
Intensified Reduced-Intensity Conditioning for Allogeneic Stem Cell Transplantation in AML or MDS
In the phase II FIGARO trial reported in the Journal of Clinical Oncology, Craddock et al found that intensified reduced-intensity conditioning with fludarabine/amsacrine/cytarabine–busulfan (FLAMSA-Bu) did not improve outcomes following allogeneic stem cell transplantation vs standard...
Can Use of Opioids Contribute to Pancreatic Cancer Risk?
Researchers have found evidence that opioid use may be an unidentified risk factor contributing to the increasing incidence of pancreatic cancer in the United States. These findings were published by Barlass et al in PLOS One. The use of prescription opioids for the management of chronic pain has...
Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers
In a comprehensive molecular characterization of the most common type of head and neck cancer, researchers from the United States and Poland have clarified the contribution of key cancer-associated genes, proteins, and signaling pathways in these cancers, while proposing possible new treatment...
Transmission of Maternal Cancer in Two Infants From Mothers With Cervical Cancer During Delivery
In a brief report published in The New England Journal of Medicine, Arakawa et al described the identification of lung cancer in two children that likely resulted from transmission of maternal cervical cancer tumor cells during vaginal delivery. As noted by the investigators, the transmission of...
Effect of COVID-19 Infection on Cancer Management
In a study reported in JCO Oncology Practice, Wu et al found that almost two-thirds of patients undergoing active cancer management who were diagnosed with COVID-19 over a 4-month period in 2020 had significant delays in planned management. Study Details The retrospective study involved data on...
Analysis of Cardiac Data Among Patients Treated With Osimertinib
As reported in the Journal of Clinical Oncology by Michael S. Ewer, MD, JD, PhD, and colleagues, an analysis of data from clinical trials of osimertinib suggests the absence of a “causal relationship” between osimertinib and cardiac failure. Study Details The study involved a post hoc assessment of ...
FDA Pipeline: Two Reviews in NSCLC, Plus Prescribing Information Update for Darolutamide
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to lorlatinib in ALK-positive non–small cell lung cancer (NSCLC) and Breakthrough Therapy designation to the combination of tiragolumab plus atezolizumab in NSCLC with high PD-L1 expression. The FDA also updated the...
Total Neoadjuvant Therapy vs Standard Therapy for Locally Advanced Rectal Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Kasi et al found that total neoadjuvant therapy was associated with improved pathologic complete response rates vs standard therapy with neoadjuvant concurrent chemoradiotherapy plus adjuvant chemotherapy in patients with...
Three vs Four Courses of Chemotherapy in Younger Patients With AML
As reported in the Journal of Clinical Oncology by Burnett et al, findings from the phase III MRC AML17 trial indicated that four courses of chemotherapy, compared to three courses, reduced the cumulative incidence of relapse and improved relapse-free survival, but not overall survival, in younger...
Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer
Many patients with prostate cancer are treated with androgen-deprivation therapy. However, patients receiving androgen-deprivation therapy often experience higher levels of fatigue, depression, and cognitive impairment. In a new study published by Hoogland et al in the journal Cancer, researchers...
Addition of Gemcitabine to Pazopanib for Refractory Soft-Tissue Sarcoma
In the German phase II PAPGEMO trial reported in JAMA Oncology, Hans-Joachim Schmoll, MD, PhD, and colleagues found that the combination of pazopanib and gemcitabine improved 12-week progression-free survival vs pazopanib alone in patients with anthracycline- or ifosfamide-refractory soft-tissue...
Study Focuses on Single-Cell Analysis of Peritoneal Carcinomatosis
Researchers profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis and defined the extensive cellular heterogeneity, as well as identified two distinct cell subtypes correlated with patient survival. The findings were published by Wang et al in Nature Medicine....
Feasibility Study of Radical Cystectomy vs Intravesical BCG for High-Grade, Non–Muscle Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Catto et al, the BRAVO-Feasibility study showed that recruitment of patients with high-grade, non–muscle invasive bladder cancer into a randomized trial comparing radical cystectomy vs intravesical bacillus Calmette-Guérin (BCG) proved difficult,...
Use of a Novel CAR T-Cell Therapy in Pediatric and Adult Patients With Advanced B-Cell ALL
Pooled results of two phase I studies, reported in The Lancet by Benjamin et al, indicate that the genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product UCART19 is active and has a manageable toxicity profile in pediatric and adult patients with relapsed...
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
On January 4, U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, MD, PhD, issued the following statement on FDA-authorized dosing schedules for each COVID-19 vaccine. Two different mRNA...
Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market
On December 29, Bristol Myers Squibb issued the following statement on nivolumab’s small cell lung cancer (SCLC) indication in the United States. In 2018, nivolumab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCLC whose disease...
Ganglioside Vaccine Plus β-Glucan for Patients With High-Risk Neuroblastoma and Prior Disease Progression
In a single-institution phase II study reported in the Journal of Clinical Oncology, Cheung et al found that a subcutaneous ganglioside G2/G3 vaccine plus oral β-glucan produced antibody responses in patients with high-risk neuroblastoma, with higher anti–GD2-IgG1 titers being associated with...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
Addition of First-Line Pembrolizumab to Chemotherapy in Metastatic Triple-Negative Breast Cancer: KEYNOTE-355
As reported in The Lancet by Javier Cortes, MD, and colleagues, the phase III KEYNOTE-355 trial has shown that the addition of pembrolizumab to chemotherapy improved progression-free survival among previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast...
Gemogenovatucel-T Maintenance in Stage III/IV Ovarian Cancer
In the phase IIb VITAL trial reported in The Lancet Oncology, Rocconi et al found that front-line maintenance with the autologous tumor cell vaccine gemogenovatucel-T did not improve recurrence-free survival vs placebo in patients with stage III/IV ovarian cancer in clinical complete response after ...
NIH RADx-rad Grants Support Investigation of Novel COVID-19 Testing and Surveillance Approaches
The National Institutes of Health (NIH) has awarded over $107 million to support new, nontraditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program will also develop platforms that can be deployed in future outbreaks of COVID-19...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
Two Leading Institutions Collaborate to Advance Treatment of Smoldering Multiple Myeloma
The Multiple Myeloma Research Foundation (MMRF) and Dana-Farber Cancer Institute have jointly announced a pioneering research collaboration in smoldering myeloma, a precursor disease to multiple myeloma. Combining the strengths of the MMRF, a leader in multiple myeloma data generation, and...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
